COVID-19 live updates: City sees fourfold increase in pediatric hospitalizations

The U.S. government announced Thursday it is pausing shipment of two monoclonal antibody treatments because they are less effective against the omicron variant.

Eli Lilly’s and Regeneron’s treatments are not being sent to states after early data revealed they were not effective at preventing severe illness or hospitalization in patients infected with omicron.

The government will continue shipping sotrovimab, a monoclonal antibody treatment made by Vir Biotechnology and GlaxoSmithKline, which appears to combat the new variant.

In a statement, the Department of Health and Human Services said it is sending 55,000 doses of sotrovimab across the country and expects to distribute an additional 300,000 doses starting in January. 

Eli Lilly and Regeneron have said they are each developing updated versions of their monoclonal antibody treatments that will work against omicron. 

-ABC News’ Sony Salzman

An ABC News analysis of federal data finds that nearly 30,000 Americans have died of COVID-19 since Thanksgiving as the omicron variant spreads across the country.

The U.S. is currently averaging more than 1,200 deaths per day, an increase of 23.3% in the last month with death rates up across almost all age groups.

Nationwide, about 161,000 new COVID cases are being reported every day, up nearly 75% in the last month.

This marks the highest daily case average since Labor Day, and means the U.S. will likely surpass the daily peaks seen during the delta-fueled wave over the summer.

Fourteen states, including New York, New Jersey, Illinois and Wisconsin, are reporting their highest daily case numbers in about a year.

-ABC News’ Arielle Mitropoulos

New studies are offering additional reassurance that AstraZeneca's monoclonal antibody drug works against omicron.

The company's EVUSHELD retains neutralization activity against omicron, according to "live" virus neutralization data from both University College Oxford and Washington University School of Medicine.

AstraZeneca announced last week that its antibody drug would likely retain protection against omicron. These studies add to that growing evidence.

AstraZeneca's monoclonal antibody was authorized on Dec. 8, but for a narrow group of people. It is authorized as a way to prevent COVID-19 among people who are immune compromised, or people who are allergic to vaccine components. It is not authorized as a way to treat COVID-19 among people who have already tested positive.

There are three monoclonal antibody treatments currently authorized to treat people who already have COVID-19. Two of those treatments -- those made by Eli Lilly and Regeneron -- appear to have very little activity against omicron. A third treatment, made by Vir and GlaxoSmithKline, appears to work against omicron but is currently in short supply. The companies are working to scale up production.

-ABC News' Sony Salzman

A Royal Caribbean ship has been blocked from entering Curacao and Aruba after 55 crew members and guests tested positive for COVID-19.

The ship, named Odyssey of the Sea, set sail from Florida on Dec. 18 and had planned to visit the Caribbean  for eight nights.

According to the cruise line, 95% of all people onboard were fully vaccinated. The crew and guests who tested positive were all “fully vaccinated and mildly symptomatic or asymptomatic.”

Close contacts of the positive patients have been placed in quarantine and will be monitored for 24 hours prior to testing.

The ship will remain at sea and is scheduled to return to Florida on Dec. 26.

-ABC News’ Mina Kaji